JP2024507810A - 高脂血症又は混合型脂質異常症に罹患しているスタチン不耐性患者における使用のためのオビセトラピブ及びエゼチミブの併用療法 - Google Patents

高脂血症又は混合型脂質異常症に罹患しているスタチン不耐性患者における使用のためのオビセトラピブ及びエゼチミブの併用療法 Download PDF

Info

Publication number
JP2024507810A
JP2024507810A JP2023549866A JP2023549866A JP2024507810A JP 2024507810 A JP2024507810 A JP 2024507810A JP 2023549866 A JP2023549866 A JP 2023549866A JP 2023549866 A JP2023549866 A JP 2023549866A JP 2024507810 A JP2024507810 A JP 2024507810A
Authority
JP
Japan
Prior art keywords
ezetimibe
obisetrapib
combination
ldl
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023549866A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024507810A5 (https=
Inventor
カステレイン，ヨハンネス・ヤーコプ・ピーテル
ディトマーシュ，マルク
デビッドソン，マイケル・ハービー
Original Assignee
ニューアムステルダム・ファルマ・ベー・フェー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニューアムステルダム・ファルマ・ベー・フェー filed Critical ニューアムステルダム・ファルマ・ベー・フェー
Publication of JP2024507810A publication Critical patent/JP2024507810A/ja
Publication of JP2024507810A5 publication Critical patent/JP2024507810A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2023549866A 2021-02-18 2022-02-18 高脂血症又は混合型脂質異常症に罹患しているスタチン不耐性患者における使用のためのオビセトラピブ及びエゼチミブの併用療法 Pending JP2024507810A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL2021050109 2021-02-18
NLPCT/NL2021/050109 2021-02-18
PCT/NL2022/050083 WO2022177428A1 (en) 2021-02-18 2022-02-18 Combination therapy of obicetrapib and ezetimibe for use in statin intolerant patients suffering from hyperlipidemia or mixed dyslipidaemia

Publications (2)

Publication Number Publication Date
JP2024507810A true JP2024507810A (ja) 2024-02-21
JP2024507810A5 JP2024507810A5 (https=) 2025-02-26

Family

ID=74844966

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023549866A Pending JP2024507810A (ja) 2021-02-18 2022-02-18 高脂血症又は混合型脂質異常症に罹患しているスタチン不耐性患者における使用のためのオビセトラピブ及びエゼチミブの併用療法

Country Status (11)

Country Link
US (1) US20240189311A1 (https=)
EP (1) EP4294387A1 (https=)
JP (1) JP2024507810A (https=)
KR (1) KR20230159380A (https=)
CN (1) CN117042770A (https=)
AU (1) AU2022223224A1 (https=)
BR (1) BR112023016682A2 (https=)
CA (1) CA3210033A1 (https=)
IL (1) IL304544A (https=)
MX (1) MX2023009613A (https=)
WO (1) WO2022177428A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12006305B2 (en) 2022-07-05 2024-06-11 Newamsterdam Pharma B.V. Salts of obicetrapib and processes for their manufacture and intermediates thereof
WO2024165395A1 (en) * 2023-02-07 2024-08-15 Newamsterdam Pharma B.V. Obicetrapib and ezetimibe combination treatment and fixed dose pharmaceutical compositions
WO2025146445A1 (en) * 2024-01-03 2025-07-10 Newamsterdam Pharma B.V. Pharmaceutical compositions of obicetrapib and ezetimibe
WO2025146262A1 (en) * 2024-01-03 2025-07-10 Newamsterdam Pharma B.V. Obicetrapib for use in the treatment of hemoglobinopathies
WO2025146446A1 (en) * 2024-01-03 2025-07-10 Newamsterdam Pharma B.V. Pharmaceutical compositions of obicetrapib
WO2025147235A1 (en) * 2024-01-03 2025-07-10 Newamsterdam Pharma B.V. Fixed dose combination composition of obicetrapib and ezetimibe

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007530443A (ja) * 2004-04-02 2007-11-01 田辺製薬株式会社 テトラヒドロキノリン誘導体およびその製法
WO2017023166A1 (en) * 2015-08-04 2017-02-09 Dezima Pharma B.V. Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and a cholesterol absorption inhibitor
JP2017505333A (ja) * 2014-02-05 2017-02-16 田辺三菱製薬株式会社 心血管疾患の治療または予防に用いるためのコレステリルエステル転送タンパク質（ｃｅｔｐ）阻害剤および当該阻害剤を含む医薬組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12006305B2 (en) * 2022-07-05 2024-06-11 Newamsterdam Pharma B.V. Salts of obicetrapib and processes for their manufacture and intermediates thereof
JP2025527686A (ja) * 2022-08-22 2025-08-22 ニューアムステルダム・ファルマ・ベー・フェー オビセトラピブ及びエゼチミブ併用治療及び固定用量医薬組成物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007530443A (ja) * 2004-04-02 2007-11-01 田辺製薬株式会社 テトラヒドロキノリン誘導体およびその製法
JP2017505333A (ja) * 2014-02-05 2017-02-16 田辺三菱製薬株式会社 心血管疾患の治療または予防に用いるためのコレステリルエステル転送タンパク質（ｃｅｔｐ）阻害剤および当該阻害剤を含む医薬組成物
WO2017023166A1 (en) * 2015-08-04 2017-02-09 Dezima Pharma B.V. Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and a cholesterol absorption inhibitor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RASHID SHIRYA: "Low LDL is better - can this be achieved with CETP inhibition therapy?", EXPERT REVIEW OF CARDIOVASCULAR THERAPY, JPN7026000069, 23 January 2020 (2020-01-23), ISSN: 0005770532 *

Also Published As

Publication number Publication date
AU2022223224A1 (en) 2023-08-24
CN117042770A (zh) 2023-11-10
IL304544A (en) 2023-09-01
MX2023009613A (es) 2023-11-09
WO2022177428A1 (en) 2022-08-25
BR112023016682A2 (pt) 2023-11-14
EP4294387A1 (en) 2023-12-27
KR20230159380A (ko) 2023-11-21
US20240189311A1 (en) 2024-06-13
CA3210033A1 (en) 2022-08-25

Similar Documents

Publication Publication Date Title
JP2024507810A (ja) 高脂血症又は混合型脂質異常症に罹患しているスタチン不耐性患者における使用のためのオビセトラピブ及びエゼチミブの併用療法
US20220152052A1 (en) Methods and compositions for treating various disorders
JP2024180450A (ja) ５－ｈｔ２ｂアゴニストの形成を阻害するための製剤およびその使用方法
EP1185274B1 (en) Drug combinations comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4
JPH07206712A (ja) ＨＭＧＣｏＡレダクターゼインヒビターを用いる心臓血管の疾患の発生の危険を予防または減少する方法
JP7304913B2 (ja) コレステリルエステル転送タンパク質阻害剤及びＨＭＧ ＣｏＡ還元酵素阻害剤を含む医薬組成物及び治療併用剤
JP2006520810A (ja) Ｓ−［２−（［［１−（２−エチルブチル）シクロヘキシル］カルボニル］アミノ）フェニル］２−メチルプロパンチオエートの経口吸収性を増加させる方法
JP7691971B2 (ja) レビー小体型認知症を処置するための組成物および方法
KR20080081358A (ko) Ｈｉｖ 인테그라제 억제제의 약동학을 개선하기 위한 방법
JP2025502266A (ja) 有害な薬物相互作用及び影響を回避するためにウパダシチニブを投与する方法
JP2024527023A (ja) Ｈｉｓ低応答者の治療
JP6202633B2 (ja) ハロフェナートまたはハロフェン酸および第２の尿酸低下薬を用いる痛風に罹っている患者の高尿酸血症の治療方法
TWI651086B (zh) 用以治療或預防心血管疾病之膽固醇酯轉蛋白質(cetp)抑制劑及包含該抑制劑之醫藥組成物
NZ521351A (en) New combination of a betablocker and a HMG-CoA reductase inhibitor which are metaprolol and rosuvastatin and the use in the treatment of atherosclerosis
JP2015512948A (ja) ハロフェナートまたはハロフェン酸および抗炎症剤を用いる痛風に罹っている患者の高尿酸血症の治療方法
JPWO2005074909A1 (ja) 併用医薬
JP6454436B1 (ja) ペマフィブラートを含有する医薬
KR20140123927A (ko) 환자 부분모집단에서의 통풍 치료 방법
JP2007513991A (ja) メタボリック症候群の処置のためのスタチンの使用
JP2017039762A (ja) ハロフェナートまたはハロフェン酸および第２の尿酸低下薬を用いる痛風に罹っている患者の高尿酸血症の治療方法
CZ20024181A3 (cs) Farmaceutické prostředky obsahující betablokátor
TW202545529A (zh) 組合療法
SK11092001A3 (sk) Kombinácia vzájomne nereagujúcich liečiv obsahujúca inhibítor hmg-coa reduktázy a inhibítor, induktor alebo substrát p450 izoenzýmu 3a4
HK40051810A (en) Pharmaceutical compositions and therapeutic combinations comprising cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors
HK1242978A1 (en) Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and hmg coa reductase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250217

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260113

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260407